-
公开(公告)号:US20100179407A1
公开(公告)日:2010-07-15
申请号:US12731980
申请日:2010-03-25
申请人: Paul V. Goode, JR. , James H. Brauker , Apurv U. Kamath , James Patrick Thrower , Victoria Carr-Brendel
发明人: Paul V. Goode, JR. , James H. Brauker , Apurv U. Kamath , James Patrick Thrower , Victoria Carr-Brendel
CPC分类号: A61B5/7203 , A61B5/0004 , A61B5/0031 , A61B5/14532 , A61B5/14539 , A61B5/14542 , A61B5/1473 , A61B5/14865 , A61B5/1495 , A61B5/7225 , A61B5/7257 , A61B5/726 , A61B5/7278 , A61B5/742 , A61B5/7475 , A61B2560/0223 , A61B2562/0247 , A61B2562/0271 , A61B2562/08
摘要: Systems and methods for minimizing or eliminating transient non-glucose related signal noise due to non-glucose rate limiting phenomenon such as ischemia, pH changes, temperatures changes, and the like. The system monitors a data stream from a glucose sensor and detects signal artifacts that have higher amplitude than electronic or diffusion-related system noise. The system replaces some or the entire data stream continually or intermittently including signal estimation methods that particularly address transient signal artifacts. The system is also capable of detecting the severity of the signal artifacts and selectively applying one or more signal estimation algorithm factors responsive to the severity of the signal artifacts, which includes selectively applying distinct sets of parameters to a signal estimation algorithm or selectively applying distinct signal estimation algorithms.
-
公开(公告)号:US20100179399A1
公开(公告)日:2010-07-15
申请号:US12730058
申请日:2010-03-23
IPC分类号: A61B5/1495 , A61B5/145
CPC分类号: A61B5/1495 , A61B5/14532 , A61B5/14542 , A61B5/14865 , A61B2560/0223 , G06F19/00
摘要: Systems and methods for processing sensor analyte data, including initiating calibration, updating calibration, evaluating clinical acceptability of reference and sensor analyte data, and evaluating the quality of sensor calibration. During initial calibration, the analyte sensor data is evaluated over a period of time to determine stability of the sensor. The sensor may be calibrated using a calibration set of one or more matched sensor and reference analyte data pairs. The calibration may be updated after evaluating the calibration set for best calibration based on inclusion criteria with newly received reference analyte data. Fail-safe mechanisms are provided based on clinical acceptability of reference and analyte data and quality of sensor calibration. Algorithms provide for optimized prospective and retrospective analysis of estimated blood analyte data from an analyte sensor.
摘要翻译: 用于处理传感器分析数据的系统和方法,包括启动校准,更新校准,评估参考和传感器分析数据的临床可接受性,以及评估传感器校准的质量。 在初始校准期间,在一段时间内评估分析物传感器数据,以确定传感器的稳定性。 可以使用一个或多个匹配的传感器和参考分析物数据对的校准集来校准传感器。 基于新收到的参考分析物数据的纳入标准,可以在评估用于最佳校准的校准集之后更新校准。 基于参考和分析物数据的临床可接受性和传感器校准的质量提供故障安全机制。 算法提供了来自分析物传感器的估计血液分析物数据的优化前瞻性和回顾性分析。
-
公开(公告)号:US20100174168A1
公开(公告)日:2010-07-08
申请号:US12730077
申请日:2010-03-23
CPC分类号: A61B5/1495 , A61B5/14532 , A61B5/14542 , A61B5/14865 , A61B2560/0223 , G06F19/00
摘要: Systems and methods for processing sensor analyte data, including initiating calibration, updating calibration, evaluating clinical acceptability of reference and sensor analyte data, and evaluating the quality of sensor calibration. During initial calibration, the analyte sensor data is evaluated over a period of time to determine stability of the sensor. The sensor may be calibrated using a calibration set of one or more matched sensor and reference analyte data pairs. The calibration may be updated after evaluating the calibration set for best calibration based on inclusion criteria with newly received reference analyte data. Fail-safe mechanisms are provided based on clinical acceptability of reference and analyte data and quality of sensor calibration. Algorithms provide for optimized prospective and retrospective analysis of estimated blood analyte data from an analyte sensor.
-
公开(公告)号:US20100036225A1
公开(公告)日:2010-02-11
申请号:US12579388
申请日:2009-10-14
申请人: Paul V. Goode, JR. , James H. Brauker , Apurv U. Kamath , James Patrick Thrower , Victoria Carr-Brendel
发明人: Paul V. Goode, JR. , James H. Brauker , Apurv U. Kamath , James Patrick Thrower , Victoria Carr-Brendel
CPC分类号: A61B5/7203 , A61B5/0004 , A61B5/0031 , A61B5/14532 , A61B5/14539 , A61B5/14542 , A61B5/1473 , A61B5/14865 , A61B5/1495 , A61B5/7225 , A61B5/7257 , A61B5/726 , A61B5/7278 , A61B5/742 , A61B5/7475 , A61B2560/0223 , A61B2562/0247 , A61B2562/0271 , A61B2562/08
摘要: Systems and methods for minimizing or eliminating transient non-glucose related signal noise due to non-glucose rate limiting phenomenon such as ischemia, pH changes, temperatures changes, and the like. The system monitors a data stream from a glucose sensor and detects signal artifacts that have higher amplitude than electronic or diffusion-related system noise. The system replaces some or the entire data stream continually or intermittently including signal estimation methods that particularly address transient signal artifacts. The system is also capable of detecting the severity of the signal artifacts and selectively applying one or more signal estimation algorithm factors responsive to the severity of the signal artifacts, which includes selectively applying distinct sets of parameters to a signal estimation algorithm or selectively applying distinct signal estimation algorithms.
-
公开(公告)号:US20100036222A1
公开(公告)日:2010-02-11
申请号:US12579339
申请日:2009-10-14
申请人: Paul V. Goode, JR. , James H. Brauker , Apurv U. Kamath , James Patrick Thrower , Victoria Carr-Brendel
发明人: Paul V. Goode, JR. , James H. Brauker , Apurv U. Kamath , James Patrick Thrower , Victoria Carr-Brendel
CPC分类号: A61B5/7203 , A61B5/0004 , A61B5/0031 , A61B5/14532 , A61B5/14539 , A61B5/14542 , A61B5/1473 , A61B5/14865 , A61B5/1495 , A61B5/7225 , A61B5/7257 , A61B5/726 , A61B5/7278 , A61B5/742 , A61B5/7475 , A61B2560/0223 , A61B2562/0247 , A61B2562/0271 , A61B2562/08
摘要: Systems and methods for minimizing or eliminating transient non-glucose related signal noise due to non-glucose rate limiting phenomenon such as ischemia, pH changes, temperatures changes, and the like. The system monitors a data stream from a glucose sensor and detects signal artifacts that have higher amplitude than electronic or diffusion-related system noise. The system replaces some or the entire data stream continually or intermittently including signal estimation methods that particularly address transient signal artifacts. The system is also capable of detecting the severity of the signal artifacts and selectively applying one or more signal estimation algorithm factors responsive to the severity of the signal artifacts, which includes selectively applying distinct sets of parameters to a signal estimation algorithm or selectively applying distinct signal estimation algorithms.
-
公开(公告)号:US07583990B2
公开(公告)日:2009-09-01
申请号:US12102745
申请日:2008-04-14
IPC分类号: A61B5/00
CPC分类号: A61B5/1468 , A61B5/0031 , A61B5/1433 , A61B5/14532 , A61B5/14546 , A61B5/1473 , A61B5/14865 , A61B5/1495 , A61B5/150022 , A61B5/4839 , A61B5/743 , A61B2560/0223 , A61B2560/04 , A61B2562/085 , G01N33/48707 , G06F19/00 , Y02A90/22 , Y02A90/26
摘要: Systems and methods for processing sensor analyte data, including initiating calibration, updating calibration, evaluating clinical acceptability of reference and sensor analyte data, and evaluating the quality of sensor calibration. During initial calibration, the analyte sensor data is evaluated over a period of time to determine stability of the sensor. The sensor may be calibrated using a calibration set of one or more matched sensor and reference analyte data pairs. The calibration may be updated after evaluating the calibration set for best calibration based on inclusion criteria with newly received reference analyte data. Fail-safe mechanisms are provided based on clinical acceptability of reference and analyte data and quality of sensor calibration. Algorithms provide for optimized prospective and retrospective analysis of estimated blood analyte data from an analyte sensor.
摘要翻译: 用于处理传感器分析数据的系统和方法,包括启动校准,更新校准,评估参考和传感器分析数据的临床可接受性,以及评估传感器校准的质量。 在初始校准期间,在一段时间内评估分析物传感器数据,以确定传感器的稳定性。 可以使用一个或多个匹配的传感器和参考分析物数据对的校准集来校准传感器。 基于新收到的参考分析物数据的纳入标准,可以在评估用于最佳校准的校准集之后更新校准。 基于参考和分析物数据的临床可接受性和传感器校准的质量提供故障安全机制。 算法提供了来自分析物传感器的估计血液分析物数据的优化前瞻性和回顾性分析。
-
公开(公告)号:US20090124878A1
公开(公告)日:2009-05-14
申请号:US12353799
申请日:2009-01-14
申请人: Paul V. Goode, JR. , James H. Brauker , Apurv U. Kamath , James Patrick Thrower , Victoria Carr-Brendel
发明人: Paul V. Goode, JR. , James H. Brauker , Apurv U. Kamath , James Patrick Thrower , Victoria Carr-Brendel
IPC分类号: A61B5/145
CPC分类号: A61B5/7203 , A61B5/0004 , A61B5/0031 , A61B5/14532 , A61B5/14539 , A61B5/14542 , A61B5/1473 , A61B5/14865 , A61B5/1495 , A61B5/7225 , A61B5/7257 , A61B5/726 , A61B5/7278 , A61B5/742 , A61B5/7475 , A61B2560/0223 , A61B2562/0247 , A61B2562/0271 , A61B2562/08
摘要: Systems and methods for minimizing or eliminating transient non-glucose related signal noise due to non-glucose rate limiting phenomenon such as ischemia, pH changes, temperatures changes, and the like. The system monitors a data stream from a glucose sensor and detects signal artifacts that have higher amplitude than electronic or diffusion-related system noise. The system replaces some or the entire data stream continually or intermittently including signal estimation methods that particularly address transient signal artifacts. The system is also capable of detecting the severity of the signal artifacts and selectively applying one or more signal estimation algorithm factors responsive to the severity of the signal artifacts, which includes selectively applying distinct sets of parameters to a signal estimation algorithm or selectively applying distinct signal estimation algorithms.
-
公开(公告)号:US20100256779A1
公开(公告)日:2010-10-07
申请号:US11654135
申请日:2007-01-17
CPC分类号: A61L31/146 , A61L31/10 , A61L31/14
摘要: A membrane for implantation in soft tissue comprising a first domain that supports tissue ingrowth, disrupts contractile forces typically found in a foreign body response, encourages vascularity, and interferes with barrier cell layer formation, and a second domain that is resistant to cellular attachment, is impermeable to cells and cell processes, and allows the passage of analytes. The membrane allows for long-term analyte transport in vivo and is suitable for use as a biointerface for implantable analyte sensors, cell transplantation devices, drug delivery devices, and/or electrical signal delivering or measuring devices. The membrane architecture, including cavity size, depth, and interconnectivity, provide long-term robust functionality of the membrane in vivo.
摘要翻译: 用于植入软组织中的膜包括支撑组织向内生长的第一结构域,破坏通常在异物反应中发现的收缩力,促进血管分布,并妨碍阻隔细胞层的形成,以及抵抗细胞附着的第二结构域是 对细胞和细胞过程不可渗透,并允许分析物通过。 该膜允许体内长期的分析物输送,并且适用于可植入分析物传感器,细胞移植装置,药物递送装置和/或电信号传递或测量装置的生物界面。 膜结构,包括腔体尺寸,深度和互连性,在体内提供膜的长期稳定的功能。
-
公开(公告)号:US20110313543A1
公开(公告)日:2011-12-22
申请号:US13210338
申请日:2011-08-15
CPC分类号: A61L31/146 , A61L31/10 , A61L31/14
摘要: A membrane for implantation in soft tissue comprising a first domain that supports tissue ingrowth, disrupts contractile forces typically found in a foreign body response, encourages vascularity, and interferes with barrier cell layer formation, and a second domain that is resistant to cellular attachment, is impermeable to cells and cell processes, and allows the passage of analytes. The membrane allows for long-term analyte transport in vivo and is suitable for use as a biointerface for implantable analyte sensors, cell transplantation devices, drug delivery devices, and/or electrical signal delivering or measuring devices. The membrane architecture, including cavity size, depth, and interconnectivity, provide long-term robust functionality of the membrane in vivo.
摘要翻译: 用于植入软组织中的膜包括支撑组织向内生长的第一结构域,破坏通常在异物反应中发现的收缩力,促进血管分布,并妨碍阻隔细胞层的形成,以及抵抗细胞附着的第二结构域是 对细胞和细胞过程不可渗透,并允许分析物通过。 该膜允许体内长期的分析物输送,并且适用于可植入分析物传感器,细胞移植装置,药物递送装置和/或电信号传递或测量装置的生物界面。 膜结构,包括腔体尺寸,深度和互连性,在体内提供膜的长期稳定的功能。
-
公开(公告)号:US07192450B2
公开(公告)日:2007-03-20
申请号:US10647065
申请日:2003-08-22
IPC分类号: A61F2/02
CPC分类号: A61L31/146 , A61L31/10 , A61L31/14
摘要: A membrane for implantation in soft tissue comprising a first domain that supports tissue ingrowth, disrupts contractile forces typically found in a foreign body response, encourages vascularity, and interferes with barrier cell layer formation, and a second domain that is resistant to cellular attachment, is impermeable to cells and cell processes, and allows the passage of analytes. The membrane allows for long-term analyte transport in vivo and is suitable for use as a biointerface for implantable analyte sensors, cell transplantation devices, drug delivery devices, and/or electrical signal delivering or measuring devices. The membrane architecture, including cavity size, depth, and interconnectivity, provide long-term robust functionality of the membrane in vivo.
摘要翻译: 用于植入软组织中的膜包括支撑组织向内生长的第一结构域,破坏通常在异物反应中发现的收缩力,促进血管分布,并妨碍阻隔细胞层的形成,以及抵抗细胞附着的第二结构域是 对细胞和细胞过程不可渗透,并允许分析物通过。 该膜允许体内长期的分析物输送,并且适用于可植入分析物传感器,细胞移植装置,药物递送装置和/或电信号传递或测量装置的生物界面。 膜结构,包括腔体尺寸,深度和互连性,在体内提供膜的长期稳定的功能。
-
-
-
-
-
-
-
-
-